Omjjara

Omjjara is a medicine used to treat splenomegaly (enlarged spleen) or other disease\-related symptoms in adults who have myelofibrosis and moderate to severe anaemia (low levels of red blood cells). Myelofibrosis is a disease in which the bone marrow becomes very dense and rigid and produces abnormal, immature blood cells. Omjjara is used both in patients who have never used medicines known as Janus kinase inhibitors (JAKi) before and in those who have been treated with the JAKi ruxolitinib. Omjjara can be used in three types of the disease: * primary myelofibrosis (also known as chronic idiopathic myelofibrosis), where the cause of the disease is unknown; * post\-polycythaemia vera myelofibrosis, where the disease is linked to an overproduction of red blood cells; * post\-essential thrombocythaemia myelofibrosis, where the disease is linked to an overproduction of platelets (components that help the blood to clot). These diseases are rare, and Omjjara was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on the EMA website ([post\-polycythaemia vera myelofibrosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-886), [post\-essential thrombocythaemia myelofibrosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-887), [primary myelofibrosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-888): 05 August 2011\). Omjjara contains the active substance momelotinib.